AltheaDx to offer Biomarker Services on Affymetrix Platform | GenomeWeb
NEW YORK (GenomeWeb News) – AltheaDx today announced that it has been named an Affymetrix authorized service provider.
 
The San Diego-based molecular testing services provider said that the deal enables it to offer biomarker discovery and development services based on Affy’s GeneChip microarray platform. It said it would use the genotyping and gene expression platform to identify new biomarkers and analyze gene pathways that are critical to the development and progression of cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.